How to Buy Akoya Biosciences Stock
Akoya Biosciences Inc
Akoya Biosciences, Inc. , a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa.
Akoya Biosciences stock last closed at $3.91, down 1.76% from the previous day, and has decreased 47.87% in one year. It has underperformed other stocks in the Medical Instruments & Supplies industry by 0.34 percentage points. Akoya Biosciences stock is currently +28.62% from its 52-week low of $3.04, and -55.57% from its 52-week high of $8.80.
As of Apr 17, 2024, there are 49.14M shares of AKYA outstanding. The market value of AKYA is $192.14M. In the past 24 hours, 184,095 AKYA shares were traded.
How to Buy Akoya Biosciences Stock
Wondering how to invest in Akoya Biosciences stock? Here's how.
- Decide where to buy Akoya Biosciences stock: You need to choose a stock brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you decide where to buy Akoya Biosciences stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Deposit money your investment account: Choose your method of payment and add your information.
- Research Akoya Biosciences stock: The Akoya Biosciences ticker symbol is AKYA. Is Akoya Biosciences stock a good investment? Should you buy shares of AKYA? How do AKYA's underlying business fundamentals look? Do top analysts think Akoya Biosciences is a good buy? Why has AKYA's stock price moved recently? (Hint: Our stock market analysis tools can help you decide if AKYA is a good stock to buy).
- Execute your AKYA buy order: Decide if you will purchase AKYA shares at the current market price or use a limit order to purchase AKYA stock at a given price.
- Track your AKYA investment: Create a watchlist to keep track of your new investment in Akoya Biosciences shares.
Step 1: Decide where to buy Akoya Biosciences stock
You need a brokerage account to access the NASDAQ market and buy AKYA stock.
Our preferred brokerage: eToro
Based on our experience, eToro is the best brokerage. eToro gives you:
- Invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world markets: From Technology to Industrials, New York to Tokyo — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by opening an account with eToro now.
Open eToro AccountStep 2: Open your brokerage account
Now that you've picked the right brokerage, the next step is to fill out some personal information so you can invest in AKYA today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal details to create a new trading account.
- Send your application by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit money your investment account
Now that you've created your account on one of the most highly reviewed stock apps, you need to deposit funds:
Check out the walkthrough below to see the process of transferring money into your new investment account.
Step 4: Research Akoya Biosciences stock
Once you have chosen the best place to buy Akoya Biosciences stock, it's crucial to evaluate their stock prior to investing, so you truly understand the risk as well as the opportunity.
Overview of key AKYA info
AKYA Due Diligence Checks
WallStreetZen was designed to help average investors perform more in-depth fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on AKYA's stock page.
Is AKYA stock overvalued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge AKYA's intrinsic value.
Using relative valuations metrics:
- AKYA could be overvalued based on its P/B ratio of 3.57x, relative to Medical Instruments & Supplies industry P/B ratio of 3.49x
You can do additional valuation research on AKYA's stock here.
Is AKYA a healthy company?
Signs that AKYA is financially healthy:
- There are more short-term assets than long-term liabilities on the AKYA balance sheet.
- AKYA has cash burn of 54552000. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the AKYA balance sheet.
Signs that AKYA is not financially healthy:
- AKYA profit margin has gone up by 0.29 percentage points in the past year, but the company is still unprofitable.
- AKYA has a relatively high debt to equity ratio of 2.35.
- AKYA has $83.82M in cash and short term investments. This is not sufficient to cover its annual cash burn of $54.55M.
Do analysts think it's a good time to buy Akoya Biosciences stock
Out of 6 sell side analysts who give forecasts on AKYA, the consensus analyst rating on AKYA is a Strong Buy
Please note that analyst ratings are not recommendations, nor are they investment advice.
Most Recent AKYA Analyst Forecasts
Tejas Savant, a bottom 13% analyst from Morgan Stanley maintains AKYA with a strong buy rating and lowers their AKYA price target from $15.00 to $8.00, on Oct 24, 2023.
You can dig deeper into what analysts are saying on the Akoya Biosciences stock forecast page.
AKYA Momentum
AKYA Revenue
Last year, AKYA revenue was $96.63M. During the past four year, AKYA's revenue has increased by 22.99% per year. This was faster than the Medical Instruments & Supplies industry average of 9.46%.
You can research AKYA's earnings and revenue performance here.
Who is buying/selling AKYA?
Over the last 12 months, executives and large shareholders at AKYA have bought more shares than they have sold.
John Frederick Ek, CFO of AKYA, was the latest AKYA insider to sell. They sold $65,080.32 worth of AKYA shares on Apr 1, 2024.
Learn more about who owns AKYA shares here.
Can I get consistent income from AKYA stock?
No, Akoya Biosciences doesn't provide an income stream by paying out dividends.
What do other investors have to say about AKYA?
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other traders have to say.
Step 5: Execute your AKYA buy order
You have two primary options:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are usually the best for newer investors. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a particular dollar amount, place a limit order.
Click the Open Trade button and your broker will place the order.
If you need additional assistance investing in stocks on eToro, watch the how to video below:
Step 6: Track your AKYA investment
Now that you own some shares in AKYA, you'll want to stay up-to-date on your company.
Start a watchlist to track your AKYA stock.
AKYA Feed
How to Buy Stock in Akoya Biosciences
To summarize, here are the 6 steps you need to take to buy Akoya Biosciences stock right now:
- Decide where to buy Akoya Biosciences stock
- Open your brokerage account
- Deposit money your investment account
- Research Akoya Biosciences stock
- Execute your AKYA buy order
- Track your AKYA investment
If you are looking for a place to buy stocks, eToro is our recommended option.
Get Started with eToro TodayIf you want to get updates on your new investment in Akoya Biosciences, add AKYA to your watchlist below.
Trending Content
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.